Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Curative and palliative treatment of adults >60 years with AML (OSHO vs German AML Intergroup standard; consolidation allograft vs chemotherapy)
2005-002833-10Phase 3Completed
- Sponsor
- German Competence Network Acute and Chronic Leukemias
- Start
- Jan 2006
- Modality
- Recombinant Proteins and Enzymes, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of mitoxantrone, cytarabine, pegfilgrastim and daunorubicin in acute myeloid leukemia (AML) (5 arms), sponsored by German Competence Network Acute and Chronic Leukemias. Primary endpoint: Event-free survival. Started Jan 2006; status: completed.
02
Drugs
mitoxantronecytarabinepegfilgrastimdaunorubicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2005-002833-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002833-10.